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Abstract
Background
We performed a case control study to see if the development of osteoradionecrosis was related to a variant allele substituting T for C at -509 of the transforming growth factor beta 1 gene (TGFB1)
Patients & Methods
A  total of 140 patients, 39 with ORN and 101 without ORN, who underwent radiotherapy for head and neck cancer with a minimum of 2 years follow-up were studied. All patients showed no signs of recurrence at this time, DNA extracted from blood was genotyped for the -509 C-T variant allele of the TGFB1 gene. 
Results
There were no significant differences in patient, cancer treatment and tumour characteristics between the two groups. Of the 39 patients who developed ORN, 9 were homozygous for the common CC allele, 19 were heterozygous and 11 were homozygous for the rare TT genotype. Of the 101 patients without ORN, the distribution was 56 (CC), 33 (CT) and 12 (TT). The difference in distribution was significant giving  an increased risk of ORN of 5.7 (95% CI:1.7-19.2) for homozygote TT patients (p=0.001) and 3.6 (95% CI CI:1.3-10.0) for heterozygotes (p=0.004) when compared to patients with the CC genotype. Post radiotherapy dento-alveolar surgery was most strongly associated with the development of ORN when the genotype was CC.
Conclusions
Our findings support the postulate that the development of ORN is related to the presence of the T variant allele at -509 within the TGFB1 gene. 


Background

In 1922, Regaud published what was arguably the first report of osteoradionecrosis (ORN) of the jaws following radiotherapy.1 Over the past 80 years, this condition has persisted in those treated for head and neck cancer, as a sequela to head and neck radiotherapy in a significant minority of patients  (2-22%).2  ORN is defined as an area of exposed bone following radiotherapy that is present for 3 months or more.3It is a late effect of radiotherapy to the jaws in common with other low turnover tissues, such as lung, liver, that are low in progenitor cells.

Although ORN may be asymptomatic, pain is a common symptom and some patients present with intractable pain. In severe cases of ORN, with the condition being potentiated by the exposed bone bathing in saliva containing bacteria, patients can present with oro-cutaneous fistulas, full thickness devitalisation of bone and pathological fracture.4 Function in terms of speech, swallowing and cosmesis may also be affected. Hence, the cost of this condition in terms of the patient’s quality of life and health economics is considerable.  Many patients require continuous medication with out-patient care,5 and over half will require a major surgical procedure involving a lengthy operation with free tissue bony transfer and microvascular surgery.6  

Factors considered as predisposing to the development of ORN include tumour-related factors (size and location), treatment-related factors (radiation dose, type of mandibular resection), immune deficiencies and malnutrition. Many patients with oral cancer have significant general medical co-morbidities and frequently have a long history of alcohol and tobacco misuse.7 The additional use of concomitant or neoadjuvant chemotherapy increases risk,8 as does fast neutron therapy9, whilst IMRT(intensity modulated radiotherapy) can reduce risk.10  All this, often combined with unsatisfactory oral hygiene, and a requirement  for post radiotherapy dental extractions, puts these patients at a  high-risk of developing ORN.  Those planning radiotherapy for patients where the radiation field is likely to encompass the mandible have conventionally arranged dental assessments, and carried out any required tooth extraction before treatment. However, despite prophylactic tooth extraction, the development of ORN can occur in 15% of patients following head and neck radiotherapy,11  and furthermore around a third of those who develop ORN have no history of dento-alveolar surgery  or other dental risk factors such as periodontal disease following radiotherapy.12

Over the previous three decades, the development of ORN has been accepted as due to a  combination of hypovascularity, osteoblast death (hypocellularity) and hypoxia. However, the mechanisms causing the damage that results in ORN in bone are likely to be similar to those occurring in other low turnover tissues. In such tissues, a radiation induced fibrosis develops (RIF).13 A key event in the progression of RIF is the activation and dysregulation of fibroblastic activity leading to tissue atrophy within the previously irradiated region, and unsurprisingly this has been termed the fibroatrophic theory of radiation damage  Transforming growth factor beta1 (TGF-β1) is the major cytokine responsible for the regulation of fibroblast proliferation and differentiation.14,15,16 Differentiated fibroblasts synthesize the collagens and proteoglycans in the extracellular matrix, and it has been suggested that an increase in these fibroblasts may cause the fibrotic phenotype.15,16,17 Radiation induces long-term TGF-β1 over expression probably owing in part to oxidative stress and an inflammatory response.14,16,18  Interestingly, elevated serum TGF-β1  levels were correlated with an increased risk of fibrosis in breast and lung cancer patients.19  
The ability to predict the risk of radiation induced normal tissue complications prior to cancer treatment has been a long sought goal in radiobiology. A number of studies comparing the genotypes of unaffected and affected patients have shown associations between the development of lung fibrosis after radiotherapy and functional polymorphisms in the TGFB1 gene. 20,21,22, Although two genetic candidates had emerged as those most likely involved in TGF-β1 over expression following radiotherapy, the C-T variant at -509 and the TGFB1 codon 10 Pro allele,  a study by Giotopoulos  et al.,24  confirming the previous findings, 20 has produced the strongest evidence yet that allelic variation C-509T in the TGFB1 gene  is part of  the genetic basis for late radiation toxicities mediated by fibrosis.  Homozygotes (TT) were found to have a 15 fold increase in fibrosis following radiation compared with  the homozygous (CC) genotype and heterozygotes were found to have a 3.6 fold increase. The allele C-509T is in the promoter region of TGFB1, and may act by elevating the secretion of TGF-β1.25

In view of this evidence from other tissues exposed to radiotherapy, it seemed likely that following radiotherapy the pathogenesis of ORN was at least partly due to the increased fibrosis of tissues, and by inference as a result of increased expression of TGF-β1, caused by an allelic variation in the promoter region of the TGFB1 gene.
Accordingly we carried out an analysis of the C-509T polymorphism of the TGFB1 gene in patients who were going to or had undergone radiotherapy for head and neck cancer. The genotypes of those patients who had developed ORN were compared with the genotypes of those who had not, to see if there was an association between ORN and the TGFB1 genotype.

Method
 Patients
A total of 140 patients from three different institutions were included in this retrospective case control study. Patients were enrolled from the Head and Neck Oncology Departments of Guy’s and St Thomas’ Hospital (n=73), University Hospital, Aintree NHS Foundation Trust, Liverpool (n=37), and the Department of Clinical Oncology, The Christie, Manchester (n=30). Ethical and trust Research and Development approvals were obtained by each participating centre. All patients consented for the use of their DNA in research. 

Inclusion criteria were as follows: head and neck cancer; radiotherapy alone or post-operatively where the field included in the mandible, including interstitial therapy; a minimum of 2 years following completion of radiotherapy or the presence of ORN. As ORN can develop at any time after radiotherapy, there is likely an underestimate of subsequent ORN in the control group but the two year period is likely to include 90% of all  cases,26  and this error rate was considered acceptable.  The study was initiated Guy’s and St Thomas’.  Any patient who attended for follow up  in whom radiotherapy was adjunctive and post-operative, was recruited over a two year time period as were those receiving radiotherapy or radiotherapy with concomitant chemotherapy. At Guy’s and St Thomas’ this included patients with ORN who had been referred for treatment of this condition from other  institutions. Patient age, sex and smoking history were noted, as were  tumour site and stage , whether resectional surgery was carried out to the primary site and /or the neck. Also  whether  post operative dental extractions or other forms of dento-alveolar surgery had been undertaken. Patients receiving both external beam radiotherapy and interstitial radiotherapy were included, where the mandible was considered to be in the field. Radiotherapy doses to this area ranged between 55 to 65 Gy administered over a period of 4-6 weeks, and 7 patients received concurrent Cisplatin and 5FU in addition to radiotherapy. No patients received epidermal growth factor targeted therapy. Following a power study and an interim analysis of the first 48 patients recruited at Guy’s and St Thomas’, further patients were enrolled from  Guy’s  and St Thomas’ and the other institutions. Patients at Liverpool all had primary surgery  and post operative radiotherapy  was at dose of 60Gy  in 30 fractions to the tumour site. At Manchester, patients, whose primary tumours had not been resected surgically, received between 50 and 52.5 Gy in 167 fractions. Patients who had surgical resection of their primary tumour or whose parotid gland was treated received 50 Gy in 20 fractions. Samples provided from the two other institutions were provided from stored material of patients meeting the selection criteria provided above, and included all samples available with the necessary ethical approval.  All patients in the study had survived without local recurrence, as further ablative tumour surgery after their initial recurrence, excluded them from the study as this might promote ONR. At Guy’s and St Thomas’ the 6 patients where ORN  had developed before 2 years were still alive and disease free 2 years after completion of treatment.

Genotyping
Blood samples were stored in an EDTA tube at -40 oC before processing.  Human genomic DNA was extracted from whole blood EDTA samples using QIAGEN MagAttract DNA Blood Midi M48 kit according to manufacturer’s instructions (QIAGEN Ltd., Crawley, UK). All DNA samples were genotyped for SNP rs1800469 (TGF-B1 C-509T) using PCR-RFLP as previously described. 20 PCR amplicons were digested with Bsu36I and the restriction fragment length pattern was interpreted after separation by agarose gel electrophoresis to differentiate between the genotypes CC (fragment lengths 190 bp + 229 bp), CT (fragment lengths 190 bp + 229 bp + 419 bp), and TT (fragment length 419 bp).



Statistical analysis
A power study assuming an allelic variation of  0.3524 and an ORN rate of 25% within the population to be studied at Guy’s and St Thomas’ indicated that 90 patients should be recruited to provide 80% power at the 5% significance level. Analysis of the first 48 patients showed that the OR (Odds Ratio) for developing ORN for patients homozygous for the T variant allele was 31.2 ( 95% CI:3.5-1379.0) vs those with the CC genotype and was 28.8  (95% CI:2.35-1376.9) for those who were CT heterozygous vs those with the CC genotype.  Following statistical advice, it was decided to increase the study number to 120-150 in order to narrow the confidence intervals, and reassess.

Data are presented as number (%) and comparisons between patients who developed ORN (ORN +ve) and those who had not (ORN –ve) were made using the Chi-squared or Fisher’s exact test, as appropriate. The risk of ORN +ve associated with different genotypes was examined by calculating odds ratios (OR) and 95% confidence intervals (CI). Analyses were carried out using Stata 11MP.
.


Results

There were no significant differences in the age, sex, smoking history, disease stage, site, surgery type, the use of interstitial therapy, (2 patients only) the addition of chemotherapy and the dose of radiotherapy in ORN +ve and ORN –ve patients (Table 1). Overall, the frequency of the T allele (0.37) was  similar to that obtained in  other studies,20,244 and  in Hardy-Weinberg equilibrium (p=0.0518). The distribution of genotypes in the ORN +ve and ORN -ve groups is shown in Table 2. Of  the 39 patients who developed ORN, 9 were homozygous for the common C allele, 19 were heterozygous and 11 were homozygous for the rare TT genotype. Of the 101 patients without ORN, the respective figures were 56 (CC), 33 (CT) and 12 (TT). A significantly higher proportion of ORN +ve patients possessed the CT (48.7%; 19/39) or TT (28.2%; 11/39) genotypes compared with   ORN –ve patients (CT: 32.7%; 33/101, TT: 11.9%; 12/101)  (p=0.002). 

The odds of ORN developing were higher in patients with at least one T allele (Table 3) with an OR of 5.70 (95% CI:1.69-19.21) for the TT  genotype (p=0.001) ,  3.58 (95%CI:1.34-10.00) for CT (p=0.004),  and 4.15 (95%CI:1.69-10.89)  for a combination of the CT and TT genotypes when compared against the wild type CC genotype (p=0.002) . In those patients who had developed ORN, there was a significant difference between the rates of dento-alveolar surgery  between those patients who had the T variant allele and those who did not (p=0.006). Where ORN had developed in 8 patients with the CC genotype,  7 (87.5%) had dento-alveolar surgery compared with only  5/19  (26.3%) of CT patients and  5/11(45.5%) of TT patients (Table 4).


Discussion

The authors carried out a detailed review of the literature and also carried out online searches using “osteoradionecrosis” and “radiotherapy damage to bone” as the MeSH headings. There have apparently been no previous studies to determine a relationship between genotype and the development of ORN.  In this study, the odds ratios for development of ORN were 5.7 for homozygotes  and 3.58 for heterozygotes carrying  the less common T allele at -509 in the TGFB1 gene and this would suggest that the development of ORN is at least partly due to genetic factors. This may explain why ORN develops in the absence of surgical trauma to the mandible in many patients.
                                           
The odds ratio for homozygotes with the variant allele (5.7) obtained by this study was lower than the  OR of 15 obtained in a post radiotherapy lung  fibrosis study  as described by Giotopoulos  et al.,24 and may represent   an underestimate of  some late osteoradionecrosis cases in the control group.  However, a recent review,26 reports a number of differing odds ratios for the development of complications after radiotherapy in  the presence of the T variant allele. In contrast to post radiotherapy fibrosis in the lungs, ORN is certainly at least partly caused by the trauma to the bone in the jaws  that occurs when dento-alveolar surgery is undertaken, and this may account for the lowered odds ratios in this study.  Consequently, perhaps it is surprising that the presence of the T variant allele as determined by this study is the single most significant causative factor in the development of ORN. Of the 39 patients who developed ORN,  30 (77%) had at least one T variant allele in their genotype, whereas only 37% of patients in this study developed ORN following some form of dento-alveolar surgery. This low rate of ORN related to dental factors may be a result of the effectiveness in multidisciplinary meetings in prescribing pre-treatment dental extractions, rendering patients dentally fit well before radiotherapy. It is interesting that dento-alveolar surgery was a causative factor of ORN in a significant greater proportion of patients with the CC genotype p= (87.5%) vs those with the CT or TT genotype (26.5% and 45.5%), and may represent the sensitivity of those with the T variant allele, to surgically induced ORN. Although the overall ORN rate was 27% in this study the T allele frequency of 0.37 shows the frequency of the T allele to be similar to that in other studies

The question this new data poses is what are the implications for treating head and neck cancer patients?   Bone is almost certainly not the only tissue that is affected by post radiation fibrosis in the head and neck region. In fact the involvement of soft tissues in post radiation fibrosis is probably more obvious, and can manifest as limitations of mouth opening, speech and swallowing. Further studies into the effect of the TGFB1 genotype on the post head and neck radiotherapy  patient should involve investigating the fibrotic effect on muscles such as those involved in mastication, swallowing and movements of the neck. 

 Tailoring radiation dose from genotype is the ultimate goal of radiogenomics, where radiation dose is varied in order to maximize tumour control while reducing damage to normal tissues. The integration of TGFB1 genetic profiling into routine head and neck radiotherapy practice would allow an increase in tumour dose for those radiation-tolerant patients lacking the variant allele thus increasing their probability of local recurrence-free survival, providing it was unlikely that the patient would require any post radiation dento-alveolar surgery.  Furthermore, a significant number of patients who receive surgery for head and neck cancer have marginal indications for adjuvant radiotherapy after analysis of their tumour’s histopathology.28  It may be that at least some of these patients whose genotype contains the T variant allele for the TGFB1 should not undergo radiotherapy. 

Patients who are deemed high risk may be offered prophylaxis to prevent ORN developing spontaneously or prior to any dental procedure or even to prevent ORN developing. There is some evidence that HBO (hyperbaric oxygen therapy) may be used prophylactically29 for those at high risk after dental procedures but this would be impractical for long term prophylaxis. Pentoxyfylline and vitamin E has been shown to heal ORN in a retrospective analysis,30 and this could be administered on a long term basis prophylactically to high risk patients.

Research into the genetics of ORN is at an early stage, and other polymorphisms may be significant as with post radiation fibrosis of the lungs.  Nevertheless the identification of the C-509T  variant at least partly explains why this condition occurs without dental surgery after radiotherapy to the mandible. More importantly this may mark the beginning of both eliminating ORN and other fibrotic complications in the head and neck, and escalating the radiotherapy dose to tolerant patients, to ultimately increase both the long term survival and quality of life of head and neck cancer patients.    
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